TY - JOUR
T1 - Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†
AU - MINT Study Group
AU - Kukimoto, Iwao
AU - Onuki, Mamiko
AU - Yamamoto, Kasumi
AU - Yahata, Hideaki
AU - Aoki, Yoichi
AU - Yokota, Harushige
AU - Konnai, Katsuyuki
AU - Nio, Ai
AU - Takehara, Kazuhiro
AU - Kamiura, Shoji
AU - Tsuda, Naotake
AU - Takei, Yuji
AU - Shimada, Muneaki
AU - Nakai, Hidekatsu
AU - Yoshida, Hiroyuki
AU - Motohara, Takeshi
AU - Yamazaki, Hiroyuki
AU - Nakamura, Keiichiro
AU - Okunomiya, Asuka
AU - Tasaka, Nobutaka
AU - Ishikawa, Mitsuya
AU - Hirashima, Yasuyuki
AU - Shimoji, Yuko
AU - Mori, Mayuyo
AU - Iwata, Takashi
AU - Takahashi, Fumiaki
AU - Yoshikawa, Hiroyuki
AU - Yaegashi, Nobuo
AU - Matsumoto, Koji
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2022/10/6
Y1 - 2022/10/6
N2 - Although geographical differences in the distribution of human papillomavirus genotypes have been observed worldwide, no studies have reported on national differences in the prevalence of human papillomavirus types in Japan. Here, we report a cross-sectional study to explore regional differences in the prevalence of human papillomavirus types among Japanese women with cervical intraepithelial neoplasia or invasive cervical cancer. Using human papillomavirus genotyping data from the nationwide prospective study on human papillomavirus vaccine effectiveness, we compared the frequency of detection of 15 high-risk and two low-risk human papillomavirus types in each disease category between the women who visited hospitals located in eastern Japan and those who visited hospitals located in western Japan. The risk of cervical intraepithelial neoplasia progression was assessed by calculating a prevalence ratio of each human papillomavirus type for cervical intraepithelial neoplasia grade 2/3 versus grade 1. Among the human papillomavirus types studied, human papillomavirus 52 was detected significantly more frequently in western hospitals than in eastern hospitals in cervical intraepithelial neoplasia grade 1 patients, but was less frequent in cervical intraepithelial neoplasia grade 2/3. The prevalence of particular human papillomavirus types was not significantly different between patients in hospitals in eastern Japan and those in hospitals in western Japan for invasive cervical cancer. In both eastern and western hospitals, a higher risk of cervical intraepithelial neoplasia progression was observed in patients infected with human papillomavirus 16, 31 or 58. In contrast, there was a significantly higher prevalence of human papillomavirus 52 infection in women with cervical intraepithelial neoplasia grade 2/3 than in those with cervical intraepithelial neoplasia grade 1 in eastern hospitals (prevalence ratio, 1.93; 95% confidence interval, 1.48-2.58), but not in western hospitals (prevalence ratio, 1.03; 95% confidence interval, 0.83-1.30). Regional differences of human papillomavirus 52 prevalence in cervical intraepithelial neoplasia lesions may exist and emphasize the importance of continuous monitoring of human papillomavirus type prevalence throughout the country in order to accurately assess the efficacy of human papillomavirus vaccines.
AB - Although geographical differences in the distribution of human papillomavirus genotypes have been observed worldwide, no studies have reported on national differences in the prevalence of human papillomavirus types in Japan. Here, we report a cross-sectional study to explore regional differences in the prevalence of human papillomavirus types among Japanese women with cervical intraepithelial neoplasia or invasive cervical cancer. Using human papillomavirus genotyping data from the nationwide prospective study on human papillomavirus vaccine effectiveness, we compared the frequency of detection of 15 high-risk and two low-risk human papillomavirus types in each disease category between the women who visited hospitals located in eastern Japan and those who visited hospitals located in western Japan. The risk of cervical intraepithelial neoplasia progression was assessed by calculating a prevalence ratio of each human papillomavirus type for cervical intraepithelial neoplasia grade 2/3 versus grade 1. Among the human papillomavirus types studied, human papillomavirus 52 was detected significantly more frequently in western hospitals than in eastern hospitals in cervical intraepithelial neoplasia grade 1 patients, but was less frequent in cervical intraepithelial neoplasia grade 2/3. The prevalence of particular human papillomavirus types was not significantly different between patients in hospitals in eastern Japan and those in hospitals in western Japan for invasive cervical cancer. In both eastern and western hospitals, a higher risk of cervical intraepithelial neoplasia progression was observed in patients infected with human papillomavirus 16, 31 or 58. In contrast, there was a significantly higher prevalence of human papillomavirus 52 infection in women with cervical intraepithelial neoplasia grade 2/3 than in those with cervical intraepithelial neoplasia grade 1 in eastern hospitals (prevalence ratio, 1.93; 95% confidence interval, 1.48-2.58), but not in western hospitals (prevalence ratio, 1.03; 95% confidence interval, 0.83-1.30). Regional differences of human papillomavirus 52 prevalence in cervical intraepithelial neoplasia lesions may exist and emphasize the importance of continuous monitoring of human papillomavirus type prevalence throughout the country in order to accurately assess the efficacy of human papillomavirus vaccines.
KW - cervical cancer
KW - cervical intraepithelial neoplasia
KW - genotyping
KW - human papillomavirus
KW - prevalence ratio
UR - http://www.scopus.com/inward/record.url?scp=85139352998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139352998&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyac127
DO - 10.1093/jjco/hyac127
M3 - Article
C2 - 35938523
AN - SCOPUS:85139352998
SN - 0368-2811
VL - 52
SP - 1242
EP - 1247
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 10
ER -